Skip to main content
Clinical Trials/NCT01623726
NCT01623726
Withdrawn
Phase 2

Transcranial Direct Current Stimulation (tDCS) as Therapeutical Strategy for Negative Symptoms in Schizophrenia: a Double-blind Randomized Clinical Trial

University of Sao Paulo1 site in 1 countryAugust 2012

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Transcranial Direct Current Stimulation
Sponsor
University of Sao Paulo
Locations
1
Primary Endpoint
Negative Symptoms Rates as assessed by the PAANS
Status
Withdrawn
Last Updated
12 years ago

Overview

Brief Summary

The current research is aimed at using Transcranial Direct Current Stimulation (tDCS) as complementary therapeutic tool in the treatment of schizophrenia. Patients will be randomized into two groups (tDCS-active x tDCS-sham) accordingly to detailed protocol. Main outcome will be measured by specific clinical rating scales based on the assessment of negative symptoms. A total of 40 patients ought to be enrolled as specified in methodology. Secondary outcomes shall include collateral effects evaluation, anxiety and depressive scales as well as clinical monitoring.

Detailed Description

Overview The present study is a double-blind randomized clinical trial in which patients should be allocated from a General Psychiatry Service into two groups (tDCS-active x tDCS-sham). Subjects who fulfilled eligibility criteria will undergo ten days of consecutive stimulation (active or sham) and will return after two to four weeks for final clinical assessment. Patients who shown no response in rating scales and that were allocated to sham intervention group will be able to choose whether or not they want to undergo the active intervention at follow up (partial cross-over)

Registry
clinicaltrials.gov
Start Date
August 2012
End Date
August 2014
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Andre Brunoni

Prof. Dr.

University of Sao Paulo

Eligibility Criteria

Inclusion Criteria

  • patients with age between 18-59 years
  • diagnostic of Schizophrenia or Schizoaffective Disorder as stated by DSM-IV and confirmed by SCID (Structured Clinical Interview for DSMIV), to be tested by a psychiatrist
  • baseline score higher than 20 for negative symptoms at PAAN
  • patients able to read and understand Portuguese.

Exclusion Criteria

  • other psychiatric diagnosis
  • criteria for bipolar disorder; dementia; other psychotic disturbs; substance related disorders
  • presence of other severe neurological or clinical diseases
  • presence of suicidal behavior (planning or attempt in the previous 4 weeks)
  • pregnancy
  • incapacity of coping with the informed consent
  • specific tDCS limitations (such as anatomic problems)
  • Regarding medication: all patients should have stable dosology of medications for at least 6 weeks

Outcomes

Primary Outcomes

Negative Symptoms Rates as assessed by the PAANS

Time Frame: Assessment at 0(baseline), 2 weeks and 4 weeks (final outcome) - Positive and Negative Syndrome Scale (PAANS)

Comparison between follow u and baseline PAANS scores with emphasis in negative symptoms scores

Secondary Outcomes

  • Mental Mini Exam(Assessment at 0(baseline), 2 weeks and 4 weeks (final outcome) - Cognitive Screening assessment as performed by the Mental Mini Exam)
  • Moca rating Scale(Assessment at 0(baseline), 2 weeks and 4 weeks (final outcome) - Cognitive assessment by MoCa Test)
  • Stroop Victoria(Assessment at 0(baseline), 2 weeks and 4 weeks (final outcome) - Cognitive assessment by Stroop - Victoria version)
  • Neuropsychological Assessment(Assessment at 0(baseline), 2 weeks and 4 weeks (final outcome) - neuropsychologial assessment by trained researcher)

Study Sites (1)

Loading locations...

Similar Trials